Rociletinib in EGFR-mutated non-small-cell lung cancer.
By L. Sequist, J. Soria, J. Goldman, H. Wakelee, S. Gadgeel, A. Varga, V. Papadimitrakopoulou, B. Solomon, G. Oxnard, R. Dziadziuszko and 20 more. New England Journal of Medicine, 2015
627 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/02ef2af56b90a67711ae6c6067acff7969cf7443
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors (2016, neutral): “Compounds of this class are demonstrating significant efficacy against T790M mutant tumors in ongoing clinical trials 17,18 , and osimertinib was recently approved by the U.S. Food and Drug Administration for patients with EGFR T790M-positive NSCLC following progression on prior EGFR TKI therapy.”
- Integrated digital error suppression for improved detection of circulating tumor DNA (2016, positive): “Given the importance of EGFR mutations for existing and emerging targeted therapies 24-26 , we subsequently tested the performance of iDES for noninvasive genotyping of EGFR-mutant NSCLCs (Supplementary Table 2).”
- Current Challenges in Cancer Treatment. (2016, background): “Targeted therapy against this secondary genomic event with third-generation EGFR TKIs (osimertinib or rociletinib) has changed the natural history of resistant EGFR disease, with 60% RR and preliminary 10-month median PFS in T790Mþ subsets.(58,59) As far as the second group is concerned, functional ”
- Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer (2018, neutral): “The ORR was 59% for the 46 evaluable T790M mutation-positive patients and 29% for the 17 T790M mutation-negative patients [83].”
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. (2016, background): “(rociletinib, osimertinib, HM61713/BI1482694, ASP8273, and EGF816) and all have reported objective response rates (ORRs) that exceed 45% in patients with EGFR-mutant NSCLC and T790Mpositive resistance.(12-16) Clinical activity in patients with tumors negative for T790M has been less favorable, thoug”